biotech / news / / GlobeNewswire
Xgeva (denosumab) is crucial in preventing SREs in patients with bone metastases and treating high-risk osteoporosis.
In March 2024, the MHRA approved a high-concentration Xgeva prefilled syringe formulation.
KEY POINTS
- Alvotech and Dr. Reddy's Laboratories partnered in May 2024 for a denosumab biosimilar.
- Estimates predict about 510 new annual cases of bone sarcoma in the UK by 2038-2040.
- Asia-Pacific is projected as the fastest-growing region in the Xgeva market.
COMPANIES
Summarized by Newsio from GlobeNewswire. How we summarize →